The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

ARIAD Pharmaceuticals Inc

Nasdaq: ARIA
Last

(U.S.) $13.16

Today's change0.00 0.00%
Updated December 2 4:15 PM EST. Delayed by at least 15 minutes.
 

ARIAD Pharmaceuticals Inc

Nasdaq: ARIA
Last

(U.S.) $13.16

Today's change0.00 0.00%
Updated December 2 4:15 PM EST. Delayed by at least 15 minutes.

ARIAD Pharmaceuticals Inc closed at (U.S.)$13.16.

Shares have lost 7.00% over the last five days, but have gained 110.56% over the last year to date. This security has outperformed the S&P 500 by 103.15% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $13.16
  • High--
  • Low--
  • Bid / Ask(U.S.) $12.84 / (U.S.) $13.66
  • YTD % change+110.56%
  • Volume0
  • Average volume (10-day)5,390,952
  • Average volume (1-month)8,293,840
  • Average volume (3-month)6,945,708
  • 52-week range(U.S.) $4.37 to (U.S.) $14.42
  • Beta2.08
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.18
Updated December 2 4:15 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-16.99%

Although this company's net profit margin is negative, it is above the industry average and implies that ARIAD Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.00%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2016Q2/2016Q1/2016Q4/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015
Revenue46683637
Total other revenue--------
Total revenue46683637
Gross profit45673536
Total cost of revenue1100
Total operating expense71808389
Selling / general / administrative26343644
Research & development44434445
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)023--
Other operating expenses, total--------
Operating income-25-12-48-53
Interest income (expense), net non-operating-8-5-5-5
Gain (loss) on sale of assets--------
Other--------
Income before tax-30112-54-58
Income after tax-28110-54-60
Income tax, total-2202
Net income-28110-54-60
Total adjustments to net income--------
Net income before extra. items-28110-54-60
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-28110-54-60
Inc. avail. to common incl. extra. items-28110-54-60
Diluted net income-28110-54-60
Dilution adjustment0--00
Diluted weighted average shares193195190189
Diluted EPS excluding extraordinary itemsvalue per share-0.140.56-0.28-0.32
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.140.57-0.27-0.32